Begin typing your search above and press return to search.
exit_to_app
Jifri Thangal & Joseph Kallarangatt
access_time 2021-09-22T13:54:37+05:30
My Friend Umar
access_time 2021-09-22T18:42:27+05:30
access_time 2021-09-21T12:24:36+05:30
The mechanical conscience of imperialism
access_time 2021-09-20T11:35:46+05:30
Hathras: Cant that family be spared yet?
access_time 2021-09-17T11:57:21+05:30
Fantasies of Mayawati
access_time 2021-09-16T20:37:12+05:30
DEEP READ
exit_to_app
Homechevron_rightTechnologychevron_rightVaccine against dengue ...

Vaccine against dengue to be tested in India

text_fields
bookmark_border
Vaccine against dengue to be tested in India
cancel

Paris: The world's most effective vaccine candidate against dengue is all set for trials in India and if all goes to plan, the vaccine will be available globally by 2015, says a report in a leading daily.

The vaccine will be tested on 120-odd adults in the beginning, the results of which should be available by 2013. Thereafter, a largescale study on children — the main target group — will be undertaken, said the report Monday.

In an interview the daily held with French pharma giant Sanofi Pasteur's CEO Christopher Viehbacher, it quoted him saying, "sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon."

Dr Jean Lang, head of the vaccine's R&D programme, added, "The drug controller general of India has asked us to conduct phase II safety trials on adults first, then on children. It will help us get licence to market the vaccine in India faster if it has been tested on the Indian population and is found safe and effective."

However, the report says, even the world's most effective dengue vaccine candidate, set for trials in India soon, will not be able to counter all virus strains.

There is currently no vaccine to protect against dengue, and efforts to develop one have been hamstrung since four viruses (known as DENV 1, 2, 3 and 4) cause the disease. Researchers in France and Thailand recently announced that the vaccine under trials — French pharma giant Sanofi Pasteur's CYD-TDV — was tested for its effectiveness on a group of 4,002 schoolchildren in Thailand, aged four to eleven. Secondary tests showed that the vaccine was effective against DENV 1, 3 and 4 but not on DENV 2, which appeared to be resistant. The vaccine showed a 60-90% protection rate against three main virus strains (DENV 1, 3 and 4).

Show Full Article
TAGS:
Next Story